aTYR PHARMA INC — Director's Dealing 2021

Mar 9, 2021

SEC Form 4/A — Form 4/A

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2021-02-04

Reporting Person: Shukla Sanjay (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-04	Employee Stock Option (right to buy)	$4.52	A	112469	Acquired	2031-02-04	Common Stock (112469)	Direct

Footnotes

F1: The option grant was originally intended for 120,000 shares. However, that size of grant was in excess of an annual grant limit in the Issuer's equity plan and, as a result, the portion of the award that was in excess of the plan limit was disgorged.

F2: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 4, 2021, such that this option will be fully exercisable on February 4, 2025. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.